GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Total Inventories

Angion Biomedica (Angion Biomedica) Total Inventories : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Total Inventories?

Angion Biomedica's total inventories for the quarter that ended in Mar. 2023 was $0.00 Mil. Angion Biomedica's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Mar. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Angion Biomedica's Net-Net Working Capital per share for the quarter that ended in Mar. 2023 was $0.90.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Angion Biomedica Total Inventories Historical Data

The historical data trend for Angion Biomedica's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica Total Inventories Chart

Angion Biomedica Annual Data
Trend Dec12 Dec13 Dec18 Dec19 Dec20 Dec21 Dec22
Total Inventories
Get a 7-Day Free Trial - - - - -

Angion Biomedica Quarterly Data
Jun13 Dec13 Mar14 Jun14 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Angion Biomedica Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Angion Biomedica  (NAS:ANGN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Angion Biomedica's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2023 is

Net-Net Working Capital Per Share (Q: Mar. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(29.219+0.75 * 0+0.5 * 0-2.101
-0-0)/30.1142
=0.90

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Angion Biomedica's Days Inventory for the three months ended in Mar. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2023 )/Cost of Goods Sold (Q: Mar. 2023 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Angion Biomedica's Inventory Turnover for the quarter that ended in Mar. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2023 ) / Average Total Inventories (Q: Mar. 2023 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Angion Biomedica's Inventory to Revenue for the quarter that ended in Mar. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Angion Biomedica Total Inventories Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Angion Biomedica (Angion Biomedica) Business Description

Traded in Other Exchanges
N/A
Address
7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Executives
Jay Venkatesan director, officer: See Remarks C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes officer: See Remarks C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi director
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc 10 percent owner C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553